




RealRate

# PHARMACEUTICAL 2016

Aeolus Pharmaceuticals INC  
Rank 268 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Aeolus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeolus Pharmaceuticals INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Aeolus Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 239% points.

The company's Economic Capital Ratio, given in the ranking table, is 101%, being 162% points below the market average of 263%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 1,745                |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 2,622                |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 32                   |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 2.0                  |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 3,111                |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 0                    |
| Research and Development                    | 3,509                |
| Selling, General and Administrative Expense | 2,228                |

| Output Variable             | Value in<br>1000 USD |
|-----------------------------|----------------------|
| Assets                      | 1,777                |
| Liabilities                 | 2,622                |
| Expenses                    | 5,739                |
| Revenues                    | 0                    |
| Stockholders Equity         | -845                 |
| Net Income                  | -2,628               |
| Comprehensive Net Income    | -2,628               |
| BaseVar                     | 6,624                |
| ECR before LimitedLiability | -203%                |
| Economic Capital Ratio      | 101%                 |